Status:
UNKNOWN
Mesenchymal Stem Cell Infusion for COVID-19 Infection
Lead Sponsor:
Dr. Zaineb Akram
Conditions:
COVID-19
Eligibility:
All Genders
10+ years
Phase:
PHASE2
Brief Summary
Since the outbreak of coronavirusdisease2019(COVID-19), many researchers in China have carried out/published clinical trials on treatment based on Western medicine, traditional Chinese medicine or a c...
Detailed Description
All patients will receive 2x10\^6 cells/kg on days 1 and day 7 (if needed). The study will be divided in 2 phases. In the first phase, 10 patients will be included and randomized to 2 groups (5 Treatm...
Eligibility Criteria
Inclusion
- Male or female, aged ≥ 10years
- Laboratory confirmation of COVID19 infection by reverse-transcription polymerase chain reaction (RT-PCR) from any diagnostic sampling source; and
- Moderate illness: In compliance with the 2019-coronavirus pneumonia diagnosis standard \[according to the novel coronavirus infection pneumonia diagnosis and treatment program (Trial Implementation Version 6) issued by the National Health and Medical Commission, and world health organization (WHO) 2019 new coronavirus guidelines standards\]: (A) increased breathing rate (≥30 beats / min), difficulty breathing, cyanosis of the lips; (B) in resting state, means oxygen saturation ≤93%; (C) partial pressure of arterial oxygen (PaO2) / Fraction of inspired oxygen (FiO2) ≤300 mmHg (1mmHg = 0.133kPa);
- Critically ill : Respiratory failure, Septic Shock, muti-organ dysfunction syndrome (MODS)
Exclusion
- Patients with systemic autoimmune diseases
- Not consenting for clinical trial
- Those declared not for resuscitation due to underlying comorbid or current critical condition
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04444271
Start Date
May 1 2020
End Date
September 30 2020
Last Update
June 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NIBMT
Rawalpindi, Punjab Province, Pakistan, 46000